<DOC>
	<DOC>NCT01869881</DOC>
	<brief_summary>Phase 4 Study to evaluate the safety and effect on decreasing subjects' albuminuria who have Type 2 Diabetes by using sarpogrelate and placebo.</brief_summary>
	<brief_title>Effect of Sarpogrelate On the Nephropathy in Type 2 Diabetes (SONATA Study)</brief_title>
	<detailed_description />
	<mesh_term>Kidney Diseases</mesh_term>
	<mesh_term>Diabetic Nephropathies</mesh_term>
	<mesh_term>Sarpogrelate</mesh_term>
	<criteria>person who signed on ICF Type 2 diabetic patient who have microalbuminuria or overt proteinuria In case of hypertension patients, who keep the same medication steadily over last 4 weeks patients who have hypersensitivity on sarpogrelate or other salicylic acid patients who should keep the antiplatelet agent because of acute cardiac disease or peripheral vein disease patients who took other anticoagulant agent within 1 month patient who take ACEI OR ARB but not controlled(over 150/100mmHg) Type 1 diabetes patients Patient who have cardiac or liver problem Cr: &gt;1.8mg/dl or GFR: &lt;40ml/min malignant tumor patients</criteria>
	<gender>All</gender>
	<minimum_age>20 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>July 2014</verification_date>
</DOC>